Protection against West Nile virus and Lyme
Bayer: New tick product for dogs
set to take global veterinary market by storm
Launch to follow regulatory approval in the
USALeverkusen – Bayer HealthCare's Animal Health Division
in the USA is getting off to a great start in 2003 with a
new veterinary product to combat ticks, fleas and mosquitoes.
The new product eliminates the vectors that transmit Lyme
disease and West Nile virus, two diseases that represent a
danger to humans too. Following a record development time
of just three years and recent regulatory approval in the
USA, the product is scheduled for submission to the authorities
in countries worldwide in the next few years.
Members of the international scientific community
and research scientists from Bayer today presented the new
product to more than 10,000 experts and veterinarians attending
the North American Veterinary Conference in Orlando, Florida.
The company expects the new flea and tick treatment for dogs
to become one of the most successful products in the veterinary
West Nile virus is endemic in certain regions
of the USA and is threatening to spread to Europe. Lyme disease
is a serious bacterial infection which is common both in the
USA and in Europe.
Bayer HealthCare, a subgroup of Bayer AG, is
one of the world's leading innovative healthcare companies,
supplying drugs and medical products. It has sales of around
EUR 10 million. The Bayer subgroup combines the activities
of the Animal Health, Biological Products, Consumer Care,
Diagnostics and Pharmaceuticals Divisions and employs more
than 34,000 people worldwide.
Bayer HealthCare develops, manufactures and
distributes innovative products for medical diagnostics, preventive
healthcare and therapeutic purposes which make an important
contribution to improving the health of people and animals
throughout the world.
The Animal Health Division has sales of around
EUR 860 million (2001) and is one of the world's leading manufacturers
of veterinary drugs for livestock and companion animals. Its
product portfolio includes major offerings such as Advantage®,
an innovative flea treatment for dogs and cats, antibiotics
to treat serious bacterial infections and worming agents.